Ryon P. Graf - Fdn Med Inc | 人才画像

基本信息

浏览量：2

职业迁徙

个人简介

I am interested in the commercial scaling and clinical evidentiary build of liquid biopsy biomarkers that can improve the treatment and outcomes of patients with cancer. I am fluent in R, data wrangling, and have practical experience in applied clinical biostatistics.

研究兴趣

论文共 196 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

ESR1 mutations (ESR1mut) in HR(+)HER2(-)patients with metastatic breast cancer (MBC): prevalence along treatment course and predictive value for endocrine therapy (ET) resistance in real-world practice

Manali Bhave,Julia Quintanilha,Ryon Graf, Takara Scott,Hanna Tukachinsky,Gerald Li,Alexa Schrock,Geoffrey Oxnard,Mia Levy, Kevin Kalinsky

CANCER RESEARCHno. 9 (2024)

引用0浏览0引用

Prognostic Value of Baseline Circulating Tumor DNA (ctdna) Tumor Fraction (TF) in Metastatic Hormone-Sensitive Prostate Cancer (Mhspc)

Charles B. Nguyen, Irene Tsung,Jessica K. Lee, Lincoln W. Pasquina,Amy Kasputis, Jennie L. Lovett,Ryon P. Graf, Frank Cameron Cackowski, Elisabeth I. Heath,Todd Matthew Morgan,Zachery R. Reichert

Journal of Clinical Oncologyno. 16_suppl (2024): 5085-5085

引用0浏览0引用

Supplementary Figure S11 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer